Von Willebrand Disease (vWD) Treatment Market Growth Rate, Statistics, Segment and Forecasts To 2026| Octapharma AG, Grifols, S.A., Shire plc

 

Von Willebrand disease is a rare condition that requires government assistance in the form of research money, treatment centres, and public awareness. As a result, governments and government organisations in several countries have devoted their attention to this bleeding illness. Due to advantages over replacement therapy, such as a lower risk of an allergic reaction, viral infection, and disease transfer, recombinant VWF (genetically designed von Willebrand factor product) is gaining popularity. The global von Willebrand disease treatment market is expected to grow as the usage of recombinant therapy rises.

During the forecast period, the worldwide von Willebrand disease treatment market is expected to be propelled by a strong product pipeline and an increase in the number of patient assistance programmes. The global von Willebrand disease treatment market was valued at US$ 471.1 Mn in 2019, according to the analysis, and is expected to grow at a CAGR of 6% from 2020 to 2030. Von Willebrand disease is an inherited bleeding illness caused by von Willebrand factor deficiency or malfunction (VWF). Furthermore, one of the reasons of von Willebrand disease is a genetic mutation. VWF shortage or defects can cause bleeding by affecting platelet adhesion or lowering FVIII concentration. Desmopressin, clot-stabilizing medicines, replacement therapy, and contraceptives are only a few of the treatments available for von Willebrand disease. An increase in the number of patient assistance programmes and demand for recombinant medicines can be attributed to the growth of the worldwide von Willebrand disease therapy market.

In 2019, the the global market for von Willebrand disease treatment was dominated by North America. During the forecast period, this tendency is expected to continue. The market in North America is expected to grow due to the well-structured healthcare industry and an increase in disease incidence. In addition, the presence of key market companies focused on the design and development of innovative treatment options for von Willebrand disease is expected to drive the market in North America. The Asia Pacific area of the global von Willebrand disease therapy market is expected to be quite profitable. During the predicted period, it is expected to grow rapidly.

The global von Willebrand disease therapy market has been divided into desmopressin, clot-stabilizing drugs, replacement therapies, contraceptives, and others in terms of drugs. Due to its great effectiveness in the treatment of von Willebrand disease, the desmopressin segment accounted for a significant part of the worldwide von Willebrand disease therapy market in 2019. The first-line treatment for von Willebrand disease is desmopressin. The segment is expected to be driven by the increasing usage of desmopressin in the treatment of VWD.

In terms of the number of participants, the global von Willebrand disease therapy market is fragmented. Octapharma AG, Grifols, S.A., Shire plc, Bayer AG, CSL Behring, Pfizer, Inc., Akorn, Inc., and Ferring B.V. are some of the major competitors in the global market.